Full Title
A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast CancerPurpose
Researchers are seeking the best dose of BMS-986500 to give alone and with other drugs in people with solid tumors. The people in this study have ovarian, endometrial, gastroesophageal, or breast cancer. Their tumors have spread beyond their original locations.
Most of the patients in this study will take BMS-986500 alone. Some of those with hormone receptor-positive HER2-negative breast cancer will get take BMS-986500 with palbociclib and fulvestrant.
BMS-986500 works by targeting and destroying a protein called Cyclin E1. Cyclin E1 is important for controlling cell division; some solid tumors make too much of it. By blocking this protein, BMS-986500 may help slow or stop the growth of your cancer. BMS-986500 is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have ovarian, endometrial, gastroesophageal, or breast cancer that has spread beyond its original location or cannot be surgically removed.
- Have cancer that cannot be successfully treated with standard therapies.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call 646-888-4226.